Related Experiment Video
Updated: Oct 11, 2025
06:12
Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots
Published on: July 21, 2023
731
[COVID-19, vaccines, and thrombotic events]
Maurizio Giuseppe Abrignani1, Adriano Murrone2, Leonardo De Luca3
1U.O. Cardiologia, P.O. Sant'Antonio Abate, ASP Trapani, Erice (TP).
Giornale Italiano Di Cardiologia (2006)
|November 30, 2021
Summary
COVID-19 infection and adenovirus-based vaccines can cause rare thrombotic events. Experts emphasize that the benefits of COVID-19 vaccination significantly outweigh the minimal risks of thrombosis.
Area of Science:
- Cardiology
- Immunology
- Virology
Background:
- COVID-19 is linked to cardiovascular complications, including thromboembolic events, potentially due to the viral spike protein.
- Adenovirus-based vaccines, while crucial for prevention, have been associated with rare cases of vaccine-induced immune thrombotic thrombocytopenia (VITT).
- VITT is characterized by thrombosis at unusual sites and thrombocytopenia, possibly due to anti-PF4 antibodies.
Purpose of the Study:
- To review epidemiological data, clinical findings, and pathogenetic hypotheses of thrombosis associated with COVID-19 and its vaccines.
- To provide cardiologists with evidence-based information for patient counseling.
- To address patient concerns regarding cardiovascular risks of COVID-19 and vaccination.
Main Methods:
- Comprehensive literature review of epidemiological studies.
- Analysis of clinical data on thrombosis in COVID-19 patients and vaccine recipients.
- Examination of pathogenetic hypotheses, including immunological mechanisms.
Main Results:
- COVID-19 significantly increases the risk of venous and arterial thromboembolic events.
- Vaccine-induced immune thrombotic thrombocytopenia is a rare but serious adverse event linked to adenovirus-based vaccines.
- The risk of thrombosis from COVID-19 disease is substantially higher than the risk associated with vaccination.
Conclusions:
- Cardiologists must be informed about the thrombotic risks of both COVID-19 and vaccines.
- Patient counseling should emphasize that the benefits of vaccination outweigh the rare risks.
- Further research into the mechanisms of VITT is warranted.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.0K
01:29Venous Thrombosis III: Interprofessional Care
55
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
55
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
734
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
734
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
64
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
64
01:30Venous Thrombosis I: Introduction
72
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
72